As of today (2024-05-27), Fortrea Holdings's share price is €23.00.
Fortrea Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €1.15. Hence, Fortrea Holdings's Price-to-Free-Cash-Flow Ratio for today is 20.00.
The historical rank and industry rank for Fortrea Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:
FRA:K67'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.44 Med: 21.45 Max: 32.95
Current: 21.56
During the past 4 years, Fortrea Holdings's highest Price-to-Free-Cash-Flow Ratio was 32.95. The lowest was 11.44. And the median was 21.45.
FRA:K67's Price-to-Free-Cash-Flow is ranked better than 65.07% of 209
companies
in the Biotechnology industry
Industry Median: 31.53
vs FRA:K67: 21.56
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Fortrea Holdings was 13.50% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -10.60% per year.
During the past 4 years, Fortrea Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was -10.60% per year. The lowest was -10.60% per year. And the median was -10.60% per year.
Fortrea Holdings Price-to-Free-Cash-Flow Historical Data
The historical data trend for Fortrea Holdings's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fortrea Holdings's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Fortrea Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's Price-to-Free-Cash-Flow falls into.
Fortrea Holdings's Share Price of today is €23.00. Fortrea Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Fortrea Holdings Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Fortrea Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:K67 has been successfully added to your 